Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Verteporfin ocular photodynamic therapy.

Sophie J Bakri1, Peter K Kaiser

  • 1Cole Eye Institute, The Cleveland Clinic Foundation, 9500 Euclid Avenue, Cleveland, OH 44195, USA.

Expert Opinion on Pharmacotherapy
|December 19, 2003
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Quality Improvement in Vitreoretinal Surgery: Single-Center Report on Utility of Routine Intravenous Fluids in Pars Plana Vitrectomy.

Journal of vitreoretinal diseases·2026
Same author

EFFICACY AND SAFETY OF THE PROPOSED BIOSIMILAR AFLIBERCEPT, SDZ-AFL, IN PATIENTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION: 52-Week Results From the Phase 3 Mylight Study: Erratum.

Retina (Philadelphia, Pa.)·2026
Same author

Long-term Outcomes of Faricimab in Previously Treated Neovascular Age-related Macular Degeneration.

Ophthalmic surgery, lasers & imaging retina·2026
Same author

Tyrosine kinase inhibitors for wet age-related macular degeneration: The current developmental landscape.

The Journal of pharmacology and experimental therapeutics·2026
Same author

Swept-Source OCT and OCT Angiography B-Scan Analysis of Inflammatory Retinal Vascular Changes: Quantitative and Qualitative Assessment.

Ophthalmology. Retina·2026
Same author

TALON phase IIIb study: 64 week results of brolucizumab versus aflibercept using treat-and-extend for neovascular age-related macular degeneration.

Eye (London, England)·2025

Verteporfin (Visudyne) is an effective treatment for specific causes of vision loss, particularly choroidal neovascularization in age-related macular degeneration. Clinical trials confirm its therapeutic benefits and safety profile for ocular photodynamic therapy.

Area of Science:

  • Ophthalmology
  • Pharmacology
  • Medical Therapy

Background:

  • Verteporfin (Visudyne) is a key therapeutic agent in ocular photodynamic therapy.
  • Understanding its pharmacotherapeutics is crucial for treating various retinal conditions.

Purpose of the Study:

  • To review the chemistry, pharmacokinetics, and pharmacodynamics of verteporfin.
  • To summarize clinical trial data on verteporfin for treating subfoveal choroidal neovascularization.
  • To discuss the safety and side effect profile of verteporfin.

Main Methods:

  • Review of scientific literature and clinical trial data.
  • Analysis of pharmacotherapeutic properties including chemistry, pharmacokinetics, and pharmacodynamics.
  • Evaluation of multi-center, randomized, controlled clinical trials.

Related Experiment Videos

Main Results:

  • Verteporfin demonstrated efficacy in treating subfoveal choroidal neovascularization associated with age-related macular degeneration, ocular histoplasmosis syndrome, and pathologic myopia.
  • Clinical trials provided robust data on treatment outcomes.
  • The safety profile and potential side effects were systematically evaluated.

Conclusions:

  • Verteporfin is a valuable therapeutic option for specific forms of choroidal neovascularization.
  • Ocular photodynamic therapy with verteporfin offers a proven treatment strategy.
  • Further understanding of its long-term effects and safety is supported by the reviewed data.